How Trump's Efforts to Lower Drug Prices Affect the Industry - 4 Questions on a Possible Executive Order - Becker's Hospital Review

Michael Strazzella, Practice Group Leader of Buchanan's Federal Government Relations practice and head of Buchanan's Washington D.C. office, and William Garvin, Shareholder in the firm's FDA/Biotechnology practice, discuss President Trump's efforts to reform drug pricing and potential implications on insurance and pharmaceutical companies in Becker's Hospital Review's "How Trump's Efforts to Lower Drug Prices Affect the Industry - 4 Questions on a Possible Executive Order."